This May, the Foundation for Prader-Willi Research (FPWR) is mobilizing people around the world affected by Prader-Willi syndrome (PWS) to raise awareness about the disease and host fundraising activities to advance disease research. This year’s PWS Awareness Month came to be thanks to the efforts of Republican…
News
FFF Enterprises and Bionews announced today that both rare and orphan disease advocates are joining forces to provide patients with resources to help them connect as a community and continue to manage their health during this time when many are finding themselves alone. Recognized as the nation’s leading supplier of…
While there are few silver linings to the cloud created by COVID-19, the pandemic that has killed tens of thousands, hobbled economies worldwide and drove millions to quarantine in their homes, one may be a new appreciation of telemedicine. “If something good could come out of this crisis, it’s that…
The approach used by diazoxide choline controlled-release (DCCR), Soleno Therapeutics’ investigational oral therapy to reduce appetite in people with Prader-Willi syndrome (PWS), has shown promise in improving insulin sensitivity and reducing body fat in several animal models of obesity linked to excessive eating. The findings were…
The National Organization for Rare Disorders (NORD) has opened a financial assistance program for people in the rare disease community who are affected by the COVID-19 pandemic in the U.S. Called the NORD COVID-19 Critical Relief Program, the effort will provide up to $1,000 annually to those eligible…
Children with Prader-Willi syndrome (PWS) struggle to express adequate facial and bodily emotions, which is linked to difficulties adapting socially, a study suggests. The study, “Equivocal expression of emotions in children with Prader-Willi syndrome: what are the consequences for emotional abilities and social adjustment?,” was published in the…
First, the bad news: If you’re one of the 30 million or so Americans with a rare disease, you probably have lower immunity to the novel coronavirus than most people. Now, the good news: You already know how to face loneliness and adversity — qualities that make you far stronger…
Millendo Therapeutics‘ treatment candidate livoletide failed to significantly reduce hunger and improve food-related behaviors in people with Prader-Willi syndrome (PWS) who are taking part in the pivotal ZEPHYR Phase 2b/3 clinical trial. Also, the treatment did not improve other measures, such as body fat, waist circumference,…
Parents and teachers attribute different severity to behavioral problems of children with Prader–Willi syndrome (PWS), according to a recent study. Although parents see food-related issues, such as repetitive speech and compulsive behavior as being more severe, teachers report that the impact of such problems on daily activities is higher. The study,…
The Living Rare, Living Stronger Patient and Family Forum, originally set for May 14–16 in Cleveland, Ohio, has been postponed until July 18–20 because of the coronavirus disease COVID-19 pandemic. The event’s sponsor, the National Organization for Rare Disorders (NORD),…
Recent Posts
- Most PWS patients meet nutrient targets but struggle with calorie control
- Adults with PWS need lifelong support in daily activities, study finds
- Celebrating a milestone in life with Prader-Willi syndrome
- New technique ‘wakes up’ silent genes in Prader-Willi in lab testing
- Probiotics may boost beneficial gut bacteria in Prader-Willi syndrome
- Avoiding meltdowns during the holidays with Prader-Willi syndrome
- PWS patients see weight loss, less hunger with setmelanotide in trial
- Eye-tracking test adapted to better measure hunger behaviors in PWS
- We struggled to find mental health support for our son with PWS
- How Prader-Willi families can enjoy the holiday season